^
    Back
    Association details:
    Biomarker:SIRT3 expression
    Cancer:Acute Myelogenous Leukemia
    Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    ASH 2018
    Title:

    SIRT3 Sumoylation Contributes to Chemoresistance in AML

    Published date:
    11/01/2018
    Excerpt:
    Furthermore, MV4-11 cells bearing control vector, wild type SIRT3 or SIRT3-K288R were engrafted in NSG mice. Cytarabine was administered to the xenografts to evaluate the chemoresistance in these cell line-derived xenograft (CDX) mouse models. Consistent to the in vitro data, SIRT3-K288R reduced total and mitochondrial ROS in vivo, resulted in enhanced leukemogenesis and impaired survival.
    DOI:
    https://doi.org/10.1182/blood-2018-99-110898